NLS Athera Biotechnologies

Athera Biotechnologies announces that the last patient has been dosed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure. The study completed recruitment by including 82 patients with STEMI and aims for results to be presented in 2020. The target of the study with ATH3G10 was to include […]

Athera Biotechnologies has announced that two composition of matter patents have been allowed for antibodies with binding to phosphorylcholine, PC. The PC target is part of modified phospholipids and has been characterized as an active driver of vascular inflammation. The therapeutic antibodies covered by the patents are designed to target and block PC and thereby […]

Athera Biotechnologies has completed a 57 million SEK financing from current major owners, The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc AB, together with new investor Ribbskottet AB, an investment company lead by Anders Bladh. Mr Bladh has a long background from international asset management, finance and banking as well as […]

Athera Biotechnologies announces that the the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to the fully human antibody PC-mAb, for the treatment of patients with end stage renal disease, who are preparing for or undergo hemodialysis, to prevent vascular access failure. “We are pleased that the FDA have granted orphan drug […]

Athera Biotechnologies announces that first dosing in a multiple dosing study in healthy volunteers has been done with its fully human antibody PC-mAb, less than three weeks after regulatory authority approval. “We are pleased to have executed our plans in such a timely manner and are looking forward to the results from this multiple dosing trial […]